Professor Colin Dayan
Prosiectau fel Prif Ymchwiliwr
- Morbidity and Mortality in Liothyronine treated patients: LT3 Outcome study (01.06.2018 - 31.05.2021)
- NAMIT - Novel immunotherapies for type 1 diabetes (01.08.2010 - 30.04.2015)
- Optimising the tolerogic potential of the dermal route of administration in the development of a diabetes vaccine (01.10.2010 - 31.10.2011)
- Phase 1b study of proinsulin peptide immunotherapy in new-onset type 1 diabetes (18.04.2011 - 31.08.2016)
- Phase1b study of proinsulin peptide immunotherapy in new onset type 1 diabetes with the clinical trial acronym (01.09.2016 - 28.02.2019)
Prosiectau fel Cyd-Ymchwiliwr
- Microneedle delivery of antigen-specific immunotherapy for type 1 diabetes (01.10.2014 - 30.09.2018)
- A new window into the immune response funding during Type 1 Diabetes (01.11.2017 - 31.05.2019)
- B cells in newly diagnosed type 1 diabetes (01.03.2012 - 31.07.2016)
- Bringing immunotherapy for type 1 diabetes into the clinic: New windows into the immune response (01.05.2018 - 30.04.2019)
- Cardiovascular disease research (01.11.2013 - 31.10.2016)